Identification of Multimorbid Patients With a Higher Probability of Readmission and Mortality
1 other identifier
observational
500
1 country
4
Brief Summary
A prospective qualitative quantitative study was designed to create predictive models of readmission in multimorbid patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2022
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 7, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2022
CompletedFirst Submitted
Initial submission to the registry
October 7, 2022
CompletedFirst Posted
Study publicly available on registry
October 12, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2023
CompletedSeptember 22, 2023
September 1, 2023
5 months
October 7, 2022
September 21, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Readmission
number of readmissions in the early period (transition to discharge, 1 month
1 month
Readmission
number of readmissions in the annual period
1 year
Study Arms (1)
Admitted
We will include patients who had been admitted by meeting Ollero et al categories in hospitalization ward
Interventions
Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality
Eligibility Criteria
multimorbid patients who are equivalently complex and with high risk for destabilization, difficult to manage and with mutual interrelationships.
You may qualify if:
- Patients over 18 years of age
- Patients discharged from the Internal Medicine departments of the participating centers due to acute pathology, de novo or decompensation of a chronic pathology who also present at least 2 of the cathegories of Ollero et al.
You may not qualify if:
- Patients admitted for end-of-life treatment, scheduled admissions, exacerbation of rheumatic pathology or systemic disease, study of anaemia in patients with no-known comorbidity, search for neoplasia and acute processes without associated comorbidity. -
- Failure to sign the informed consent form.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hospital Galdakao-Usansololead
- Hospital Costa del Solcollaborator
- Hospital del Marcollaborator
- Instituto de Salud Carlos IIIcollaborator
- Hospitales Universitarios Virgen del Rocíocollaborator
- Asociacion Instituto de Investigacion en Servicios de Salud Kronikgunecollaborator
Study Sites (4)
Hospital Galdakao Usansolo
Galdakao, Bizkaia, 48960, Spain
Hospital Costa del Sol
Marbella, Málaga, 29603, Spain
Hospital del Mar
Barcelona, 08003, Spain
Hospital Universitario Virgen del Rocío
Seville, 41013, Spain
Study Officials
- PRINCIPAL INVESTIGATOR
Susana García Gutiérrez, PhD
Unidad de Investigación. Hospital Galdakao-Usansolo. Osakidetza
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
October 7, 2022
First Posted
October 12, 2022
Study Start
February 7, 2022
Primary Completion
June 30, 2022
Study Completion
August 30, 2023
Last Updated
September 22, 2023
Record last verified: 2023-09